Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Clinuvel Pharmaceuticals ( (AU:CUV) ) has shared an announcement.
CLINUVEL PHARMACEUTICALS LIMITED has announced its 2025 Annual General Meeting (AGM) to be held on October 17, 2025, in Melbourne. The meeting will address the adoption of the 2025 Remuneration Report and the re-election of two Non-Executive Directors. The company has faced strikes on its 2023 and 2024 Remuneration Reports, leading to increased transparency and adjustments in executive remuneration practices. CLINUVEL benchmarks its executive pay against a global peer group to ensure competitive packages, essential for attracting and retaining talent. This strategic approach aims to align executive incentives with company performance and shareholder interests.
The most recent analyst rating on (AU:CUV) stock is a Buy with a A$11.50 price target. To see the full list of analyst forecasts on Clinuvel Pharmaceuticals stock, see the AU:CUV Stock Forecast page.
More about Clinuvel Pharmaceuticals
CLINUVEL PHARMACEUTICALS LIMITED is a global specialty pharmaceutical group focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders. The company is a pioneer in photomedicine and melanocortin peptides, offering innovative treatments for systemic photoprotection, DNA repair, and repigmentation. Its lead therapy, SCENESSE®, is approved in multiple regions for preventing phototoxicity in patients with erythropoietic protoporphyria (EPP). Headquartered in Melbourne, Australia, CLINUVEL operates in Europe, Singapore, and the USA.
YTD Price Performance: -11.68%
Average Trading Volume: 125,769
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$531.3M
For detailed information about CUV stock, go to TipRanks’ Stock Analysis page.